Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of cancer and planned to receive chemotherapy in 1, 2, 3, or 4 weekly schedules for a minimum of 8 weeks~* have a hemoglobin level of \>10 grams per deciliter and \<= 12 grams per deciliter within 14 days before the start of the first on-study chemotherapy cycle~* Eastern Cooperative Oncology Group (scale used by researchers to represent the level of activity a patient is capable of) score of 0 (able to carry out all normal activity without restriction) to 2 (ambulatory and capable of all self-care but unable to carry out any work)~* life expectancy of \>=6 months~* female subjects postmenopausal for at least 1 year, surgically sterile or practicing an effective method of birth control~Exclusion Criteria:~* Clinically significant or uncontrolled disease/dysfunction of any body system that is not due to cancer or chemotherapy, including uncontrolled or severe cardiovascular disease, recent (\< 6 months) myocardial infarction, uncontrolled high blood pressure, congestive heart failure, or uncontrolled or unexplained history of seizures~* planned surgery expected to influence hemoglobin levels, within the first 8 or 9 weeks of study entry~* major illness or infection within 1 month of study entry~* highly increased risk of thrombotic or other vascular events~* androgen therapy within 2 months of study entry~* anemia due to factors other than cancer/chemotherapy (e.g., severe hemolysis, gastrointestinal bleeding, or myelodysplastic syndromes)~* blood transfusion within 14 days prior to study entry~* pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).